AIMS/HYPOTHESIS: Circulating levels of adiponectin are negatively associated with multiple indices of insulin resistance, and the concentration is reduced in humans with insulin resistance and type 2 diabetes. However, the mechanisms by which adiponectin improves insulin sensitivity remain unclear. SUBJECTS AND METHODS: Combining euglycaemic-hyperinsulinaemic clamp studies with indirect calorimetry and skeletal muscle biopsies, we examined the relationship between plasma adiponectin and parameters of whole-body glucose and lipid metabolism, and muscle glycogen synthase (GS) activity in 51 Caucasians (ten lean, 21 obese and 20 with type 2 diabetes). RESULTS: Plasma adiponectin was significantly reduced in type 2 diabetic compared with obese and lean subjects. In lean and obese subjects, insulin significantly reduced plasma adiponectin, but this response was blunted in patients with type 2 diabetes. Plasma adiponectin was positively associated with insulin-stimulated glucose disposal (r = 0.48), glucose oxidation (r = 0.54), respiratory quotient (r = 0.58) and non-oxidative glucose metabolism (r = 0.38), and negatively associated with lipid oxidation during insulin stimulation (r = -0.60) after adjustment for body fat (all p < 0.01). Most notably, we found a positive association between plasma adiponectin and insulin stimulation of GS activity in skeletal muscle (r = 0.44, p < 0.01). CONCLUSIONS/ INTERPRETATION: Our results indicate that plasma adiponectin may enhance insulin sensitivity by improving the capacity to switch from lipid to glucose oxidation and to store glucose as glycogen in response to insulin, and that low adiponectin may contribute to impaired insulin activation of GS in skeletal muscle of patients with type 2 diabetes.
AIMS/HYPOTHESIS: Circulating levels of adiponectin are negatively associated with multiple indices of insulin resistance, and the concentration is reduced in humans with insulin resistance and type 2 diabetes. However, the mechanisms by which adiponectin improves insulin sensitivity remain unclear. SUBJECTS AND METHODS: Combining euglycaemic-hyperinsulinaemic clamp studies with indirect calorimetry and skeletal muscle biopsies, we examined the relationship between plasma adiponectin and parameters of whole-body glucose and lipid metabolism, and muscle glycogen synthase (GS) activity in 51 Caucasians (ten lean, 21 obese and 20 with type 2 diabetes). RESULTS: Plasma adiponectin was significantly reduced in type 2 diabetic compared with obese and lean subjects. In lean and obese subjects, insulin significantly reduced plasma adiponectin, but this response was blunted in patients with type 2 diabetes. Plasma adiponectin was positively associated with insulin-stimulated glucose disposal (r = 0.48), glucose oxidation (r = 0.54), respiratory quotient (r = 0.58) and non-oxidative glucose metabolism (r = 0.38), and negatively associated with lipid oxidation during insulin stimulation (r = -0.60) after adjustment for body fat (all p < 0.01). Most notably, we found a positive association between plasma adiponectin and insulin stimulation of GS activity in skeletal muscle (r = 0.44, p < 0.01). CONCLUSIONS/ INTERPRETATION: Our results indicate that plasma adiponectin may enhance insulin sensitivity by improving the capacity to switch from lipid to glucose oxidation and to store glucose as glycogen in response to insulin, and that low adiponectin may contribute to impaired insulin activation of GS in skeletal muscle of patients with type 2 diabetes.
Authors: M Möhlig; U Wegewitz; M Osterhoff; F Isken; M Ristow; A F H Pfeiffer; J Spranger Journal: Horm Metab Res Date: 2002 Nov-Dec Impact factor: 2.936
Authors: Kurt Højlund; Krzysztof Wrzesinski; Peter Mose Larsen; Stephen J Fey; Peter Roepstorff; Aase Handberg; Flemming Dela; Jørgen Vinten; James G McCormack; Christine Reynet; Henning Beck-Nielsen Journal: J Biol Chem Date: 2003-01-16 Impact factor: 5.157
Authors: Kurt Højlund; Peter Staehr; Bo Falck Hansen; Kevin A Green; D Grahame Hardie; Erik A Richter; Henning Beck-Nielsen; Jørgen F P Wojtaszewski Journal: Diabetes Date: 2003-06 Impact factor: 9.461
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: Craig S Stump; Kevin R Short; Maureen L Bigelow; Jill M Schimke; K Sreekumaran Nair Journal: Proc Natl Acad Sci U S A Date: 2003-06-13 Impact factor: 11.205
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440
Authors: J Giebelstein; G Poschmann; K Højlund; W Schechinger; J W Dietrich; K Levin; H Beck-Nielsen; K Podwojski; K Stühler; H E Meyer; H H Klein Journal: Diabetologia Date: 2012-01-27 Impact factor: 10.122
Authors: B F Vind; C Pehmøller; J T Treebak; J B Birk; M Hey-Mogensen; H Beck-Nielsen; J R Zierath; J F P Wojtaszewski; K Højlund Journal: Diabetologia Date: 2010-10-13 Impact factor: 10.122
Authors: B F Vind; J B Birk; S G Vienberg; B Andersen; H Beck-Nielsen; J F P Wojtaszewski; K Højlund Journal: Diabetologia Date: 2012-02-10 Impact factor: 10.122
Authors: K Højlund; Z Yi; N Lefort; P Langlais; B Bowen; K Levin; H Beck-Nielsen; L J Mandarino Journal: Diabetologia Date: 2009-12-12 Impact factor: 10.122
Authors: Pontus Boström; Linda Andersson; Birgitte Vind; Liliana Håversen; Mikael Rutberg; Ylva Wickström; Erik Larsson; Per-Anders Jansson; Maria K Svensson; Richard Brånemark; Charlotte Ling; Henning Beck-Nielsen; Jan Borén; Kurt Højlund; Sven-Olof Olofsson Journal: Diabetes Date: 2010-05-11 Impact factor: 9.461
Authors: Navabeh Zare-Kookandeh; Marjan Mosalman Haghighi; Hassane Zouhal; Ali Daraei; Maysa de Sousa; Mohammad Soltani; Abderraouf Ben Abderrahman; Jed M Tijani; Anthony C Hackney; Ismail Laher; Ayoub Saeidi Journal: Rev Endocr Metab Disord Date: 2021-04-30 Impact factor: 6.514